Robert J Gould sold $163k of FULC
director at Fulcrum Therapeutics, Inc.. 15,000 shares at an average of $10.87, traded Jan 2, 2026, filed Feb 4, 2026.
Score components
- +15RoleDirector
- +11Trade size$163k at market
- 0Share of holdings soldSold 3.1% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -17.5%, 3m -28.2%, 6m -61.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-037606, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2026 | SOpen-market sale Common Stock10b5-1 | -15,000 | $10.87 | $163k | 469,864 | Feb 4, 2026 |
Related signals
Other insiders at Fulcrum Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 49Moderate | FULCbuy Fulcrum Therapeutics, Inc. | Kevin C Tang owner | $595k 167,616 shares | +2% | |
| 48Moderate | FULCbuy Fulcrum Therapeutics, Inc. | Kevin C Tang owner | $891k 249,946 shares | +4% | |
| 23Weak | Fulcrum Therapeutics, Inc. | Alan Ezekowitz director | $66k 18,000 shares | -62% | |
| 6Weak | Fulcrum Therapeutics, Inc. | Robert J Gould director | $161k 15,000 shares | -3% | |
| 7Weak | Fulcrum Therapeutics, Inc. | Robert J Gould director | $178k 15,000 shares | -3% | |
| 19Weak | Fulcrum Therapeutics, Inc. | Curtis Gale Oltmans Chief Legal Officer | $45k 3,452 shares | -25% | |
| 55Moderate | Fulcrum Therapeutics, Inc. | Ra Capital Management, L.p. owner | $58M 4,175,139 shares | -41% | |
| 6Weak | Fulcrum Therapeutics, Inc. | Robert J Gould director | $165k 15,000 shares | -3% | |
| 15Weak | FULCsell Fulcrum Therapeutics, Inc. | Greg Tourangeau Principal Accounting Officer | $2,520 498 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.